NCT00716417 2025-08-05
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
25 trialsNCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
NCT01214616 2025-02-07
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02171650 2025-01-23
BIBW 2992 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT04410653 2024-04-05
Afatinib in Advanced NRG1-Rearranged Malignancies
German Cancer Research Center
Phase 2 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05467189 2022-07-20
Antineoplastic Drugs in Elderly Patients
Shandong University
Recruiting
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT04533321 2020-08-31
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
National University Hospital, Singapore
Phase 2 Unknown
NCT03652233 2019-06-20
Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01206816 2019-02-01
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03486509 2018-04-03
Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Unknown
NCT02020577 2017-06-22
Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01251653 2016-05-30
A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
Boehringer Ingelheim
Completed
NCT00809133 2016-03-14
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00998296 2015-08-19
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
Boehringer Ingelheim
Phase 1 Completed
NCT02171663 2015-01-28
Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02171637 2014-06-24
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02171676 2014-06-24
BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02171702 2014-06-24
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02171728 2014-06-24
Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02171741 2014-06-24
Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT01169675 2014-06-09
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00730821 2009-08-21
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
Boehringer Ingelheim
Phase 1 Completed